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Transcriptional Suppression of Interleukin-12
Gene Expression following Phagocytosis
of Apoptotic Cells
ptotic and secondary necrotic cells including oligo-
somes, might lead to an activation of autoreactive T cells
(Voll et al., 1997). The process of removing dead cells
is carried out by a wide variety of cell types and involves
multiple receptors, such as scavenger receptors, oxi-
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pressed on apoptotic cells (Savill and Fadok, 2000).
Cytokines play significant roles in the etiology and
pathology of many autoimmune diseases. The uptakeSummary
of apoptotic cells by phagocytes is thought to suppress
autoimmune responses through the release of IL-10,Phagocytosis of apoptotic cells usually results in an
anti-inflammatory state with inhibition of proinflam- TGF-, PAF, and PGE2 and inhibition of TNF-, GM-
CSF, IL-12, IL-1, and IL-18 production (Voll et al., 1997).matory cytokines such as IL-12. How apoptotic cell-
derived signals regulate IL-12 gene expression is not Produced primarily by macrophages and dendritic cells
(DCs), IL-12 is a heterodimeric cytokine that links theunderstood. We demonstrate that cell-cell contact
with apoptotic cells is sufficient to induce profound cellular and humoral branches of the host immune de-
fense apparatus (Trinchieri, 1995). The genes encodinginhibition of IL-12 production by activated macro-
phages. Phosphatidylserine could mimic the inhibitory the two heterologous chains of IL-12, p40 and p35, are
located on different human and mouse chromosomes.effect. The inhibition does not involve autocrine or
paracrine actions of IL-10 and TGF-. We report the IL-12 is an important player in T cell-mediated autoim-
munity (Trembleau et al., 1995). Specifically, IL-12 ad-identification, purification, and cloning of a novel zinc
finger nuclear factor, named GC binding protein (GC- ministration exacerbates autoimmune phenomena by
inducing the differentiation of Th1 autoreactive cellsBP), that is induced following phagocytosis of apo-
ptotic cells by macrophages or by treatment with (Leonard et al., 1997), whereas the lack of IL-12 p40 in
genetically deficient mice or mice treated with anti-IL-phosphatidylserine. GC-BP selectively inhibits IL-12
p35 gene transcription by binding to its promoter 12 antibody abrogated diseases in experimental models
of autoimmunity such as insulin-dependent diabetesin vitro and in vivo, thus decreasing IL-12 production.
Blocking GC-BP by RNA interference restores IL-12 mellitus (IDDM) in NOD mice (Rothe et al., 1997), experi-
mental allergic encephalomyelitis (EAE) (Leonard et al.,p35 transcription and IL-12 p70 synthesis. Finally, GC-
BP itself undergoes functionally significant tyrosine 1995), experimental autoimmune uveitis (EAU) (Yokoi et
al., 1997), and collagen-induced arthritis (CIA) (McIntyredephosphorylation in response to apoptotic cells.
et al., 1996). Aberrant levels of IL-12 are produced by
macrophages isolated from young mice prone to lupusIntroduction
(MRL and NZB/W) (Liu and Beller, 2002). The diabetes-
associated quantitative trait locus, Idd4, was found toThe elimination of apoptotic cells and cell bodies by
phagocytes represents an evolutionarily conserved means be responsible for the IL-12 p40 overexpression in non-
obese diabetic (NOD) mice (Simpson et al., 2003). Into prevent exposure of surrounding tissue to potentially
cytotoxic, immunogenic, or inflammatory cellular con- human patients with SLE, elevated levels of IL-12 (or IL-
12 p40) and IL-18 are observed (Wong et al., 2000), andtents (Savill et al., 1993). Resolution of inflammation de-
pends not only on the effective removal of apoptotic the higher serum IL-12 levels are correlated with fever,
but not with renal diseases, in subjects (Spadaro etcells but also on active suppression of inflammatory
mediator production. Aberrations in either mechanism al., 2002).
In this work, we observed that phagocytosis of apo-are associated with chronic inflammatory conditions
and autoimmune disorders (Haslett et al., 1994). Animal ptotic cells by macrophages inhibited IL-12 p40 and
p35 gene expression. We investigated the molecularstudies have begun to identify some of the important
molecules in the clearance of potentially antigenic mate- mechanisms whereby the interaction between phago-
cytes and apoptotic cells impacts on the expression ofrial from the circulation, such as DNase I (Napirei et al.,
2000), serum amyloid P component (SAP) (Bickerstaff IL-12 p40 and p35 genes.
et al., 1999), C1q (Mitchell et al., 2002), and C-reactive
protein (CRP) (Du Clos et al., 1994). In human systemic Results
lupus erythematosis (SLE), impaired phagocytosis of
apoptotic material by macrophages has been reported Differential Regulation of Cytokine Production
(Herrmann et al., 1998). The impaired clearance of apo- during Phagocytosis of Apoptotic Cells
ptotic cells, resulting in an accumulation of late-apo- We found that in macrophages primed with IFN- fol-
lowed by stimulation with LPS, IL-12 p40 and p70 pro-
duction was strongly inhibited following the phagocyto-*Correspondence: xim2002@med.cornell.edu
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Figure 1. Apoptotic Cells Attenuate IL-12 Production by Activated Macrophages
(A–D) A total of 1  106 cells of human peripheral blood monocyte-derived macrophages were stimulated with IFN- and LPS. Apoptotic or
necrotic cells (2:1 ratio of apoptotic or necrotic cells/macrophages) were added with LPS. Supernatants were harvested 16 hr post-LPS
stimulation and were analyzed for the production of IL-12 p40 and (A) p70, (B) IL-10, (C) PGE2, and (D) TGF-1 by ELISA. The results of IL-
12 p40 and p70 were normalized to the cytokine levels of IFN-/LPS-activated macrophages, which were set as 100%. The data represent
the mean  SD of eight individual experiments. The results of (B)–(D) are the averages of three individual experiments with SD.
(E and F) Neutralization of (E) IL-10 and (F) TGF-1 in human macrophages. Anti-IL-10 mAb, anti-TGF-1 mAb, or an isotype-matched control
(ctl) IgG was added (10 g/ml) to the macrophage cultures. IL-12 p70 concentrations were measured by ELISA.
(G) Neutralization of IL-10 and TGF- in mouse macrophages. J774 cells were stimulated with IFN- and LPS and treated with apoptotic cells
(added at the time of LPS addition). Anti-mIL-10 (1 g/ml), anti-TGF- (2 g/ml), and control antibodies were added 1 hr before apoptotic
cells. Recombinant TGF- (10 ng/ml) and IL-10 (50 ng/ml) were added with LPS. mIL-12 p70 was measured from culture supernatant 20 hr
following LPS stimulation.
(H) TGF-1 levels in all cultures corresponding to those in (G) were measured by ELISA.
sis of apoptotic cells (Figure 1A). The production of the combinant mTGF- and IL-10 strongly suppressed IL-
12 p70 production stimulated by IFN- and LPS, use ofanti-inflammatory cytokine IL-10 (Figure 1B) and prosta-
glandin E2 (PGE2) (Figure 1C) was not significantly al- neutralizing antibodies to TGF- and IL-10 had no im-
pact on apoptotic cell-induced inhibition of IL-12. Neu-tered, whereas TGF-1 production (Figure 1D) was
greatly enhanced. To determine if autocrine IL-10 and tralization of the endogenous TGF- was complete, as
shown in the ELISA data (Figure 1H). These results indi-TGF-1 production was responsible for the suppressed
IL-12 production, neutralizing antibodies to IL-10 and cate that autocrine IL-10 and TGF- production is not
a major player in apoptotic cell-mediated inhibition ofTGF-1 were added to the macrophage culture in the
presence or absence of apoptotic cells. Although the IL-12 synthesis.
IL-10 antibody strongly enhanced IL-12 production by
activated macrophages, it was not able to restore IL-12 Cell-Cell Contact, Not Phagocytosis, Is Sufficient
for Inhibition of IL-12 Productionproduction inhibited by apoptotic cells (Figure 1E). Use
of a neutralizing antibody to TGF-1 resulted in a hetero- To determine if phagocytosis was required for the ob-
served inhibition of IL-12 production by apoptotic cells,geneous response among the six donors tested, with a
combined small increase in IL-12 p70 production inhib- we used cytochalasin D (cytoD) to block actin polymer-
ization and prevent phagocytosis without interferingited by apoptotic cells (Figure 1F). To circumvent the
problem associated with human subject variations, we with cell-cell contact. Figure 2A shows that the addition
of cytoD at increasing concentrations 30 min beforeperformed the same study in the mouse macrophage
cell line J774, which has been used extensively as a (30 min, triangle) or at the time of addition of apoptotic
cells (0 min, square) strongly inhibited the uptake ofmodel system for IL-12-related studies (Murphy et al.,
1995). As shown in Figure 1G, although addition of re- fluorescently labeled apoptotic cells (by 70%–87%).
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Figure 2. Role of Cell-Cell Contact and PS in Apoptotic Cell-Mediated Inhibition of IL-12 Production
(A) Inhibition of phagocytosis. RAW264.7 cells were plated at 2  106 cells/well in 6-well plates and were stimulated with IFN- and LPS.
Various concentrations of cytoD solubilized in DMSO were added to macrophages either 30 min before (30 min) or at the same time as LPS
(0 min). Control cells received DMSO only. TAMRA-labeled apoptotic Jurkat cells were added with LPS in a 2:1 ratio. After 1 hr of incubation,
unbound apoptotic cells were washed off (three times with PBS), and the phagocytes were harvested by using Trypsin/EDTA. Phagocytosis
was measured by FACS analysis.
(B) IL-12 p40 production in the presence of cytoD. RAW264.7 cells were stimulated with IFN- and LPS for 16 hr in the presence (triangle) or
absence (square) of apoptotic Jurkat cells and 1 or 10 M cytoD (added to all cultures 30 min before the addition of apoptotic cells). Cell-
free supernatant was harvested and assayed for IL-12 p40 production by ELISA. Data represent the mean SD of three individual experiments.
(C) Inhibition of IL-12 p40 production by PS. RAW264.7 cells were stimulated with IFN- and LPS alone or together with various concentrations
of liposomes containing PS, PC, or PE. The next day, supernatant was harvested and IL-12 p40 expression was measured by ELISA. Data
represent the mean  SE of four independent experiments.
(D) Inhibition of IL-12 p70 by PS. Human monocyte-derived macrophages were stimulated with IFN- and LPS alone or together with 1 or 10
g liposomes containing PS, PC, or PE. The next day, supernatant was harvested and IL-12 p70 expression was measured by ELISA.
(E) A total of 1  106 RAW264.7 cells were treated with IFN- and LPS alone or together with apoptotic cells or 10 g of various liposomes
containing PS, PC, or PE. The next day, supernatant was harvested. TGF-1 and IL-12 p40 were measured by sandwich ELISA. The results
are the mean  SD of two independent experiments.
Figure 2B shows that at concentrations of 1 and 10 on IL-12 p70 production in primary human macrophages
(Figure 2D), suggesting that the repressive effect of apo-M cytoD, which suppressed phagocytosis by 80%
(Figure 2A), IL-12 p40 production by the IFN-/LPS-acti- ptotic cells on IL-12 production could be mediated
through the interaction of PS with its receptor(s) on mac-vated mouse monocytic cell line, RAW264.7, remained
completely inhibited following the ingestion of apoptotic rophages.
We also determined the effects of the three liposomalcells. This finding indicates that phagocytosis of apo-
ptotic cells is not required to induce the inhibition of IL- phospholipids on TGF-1 production in RAW264.7 cells
(Figure 2E). Although PS could induce modest levels12 p40 production.
PS is a lipid that is exposed on dying cells as an early of TGF-1 in IFN-/LPS-activated macrophages (60%
increase over the control), it did not correlate with thesign of apoptotic cell death and serves as a critical
recognition molecule on apoptotic cells for clearance by 97% decrease in IL-12 p40 output. This is consistent
with the data presented in Figure 1G, suggesting nophagocytes. PS is considered to be a signaling molecule
through its interaction with certain phagocytic receptors major role of the endogenous TGF- in the regulation
of IL-12 production by apoptotic cells.such as the PS receptor (PSR) (Fadok et al., 2000), which
is expressed on the surface of activated macrophages.
Treatment of RAW264.7 macrophages with various con- Apoptotic Cells Preferentially Inhibit IL-12 p35
and IL-12 p40 mRNA Expressioncentrations of PS-containing liposomes, but neither
phosphatidylcholine (PC) nor phosphatidylethanolam- To further explore the molecular basis of the inhibition
of IL-12 production by phagocytosis of apoptotic cells,ine (PE) liposomes, induced a profound inhibition of IL-
12 p40 synthesis (Figure 2C). A similar effect was seen we analyzed the mRNA expression of cytokines in acti-
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Figure 3. Phagocytosis of Apoptotic Cells In-
hibits IL-12 p35 and p40 mRNA Expression
(A) Primary human macrophages were stimu-
lated with IFN- and LPS in the presence or
absence of apoptotic or necrotic T lympho-
cytes. Total RNA was harvested at 4 hr post-
LPS stimulation and subjected to RNase pro-
tection analysis (RPA). Lane 1, unstimulated
cells; lane 2, IFN-- and LPS-stimulated cells;
lane 3, activated cells that phagocytosed
apoptotic cells; lane 4, activated cells that
ingested necrotic cells; lane 5, positive con-
trol RNA; lane 6, negative control RNA (yeast
tRNA). This shows a representative of three
independent experiments.
(B) Quantification of inhibition of IL-12 p35
and p40 mRNA. The degree of inhibition of
IL-12 p35 and p40 mRNA expression by apo-
ptotic cells in three independent RPAs was
quantified following normalization to GAPDH
expression by using the ImageQuant soft-
ware and is shown with mean  SE.
vated human macrophages in the presence or absence in a total loss of response to apoptotic cells. Additional
analyses of the region between 13 and 21 revealedof apoptotic or necrotic cells (Figure 3A). In three inde-
pendent experiments, the levels of IL-12 p35 and p40 that the GC dinucleotide at 17/18 (Construct D) was
most critical to the response of the p35 promoter tomRNAs were reduced by82% and32%, respectively
(Figure 3B), in addition to the modest inhibition of several apoptotic cells, as substitutions of this motif resulted in
a complete loss of response to apoptotic cells, whileother proinflammatory cytokines such as IL-1, IL-1,
and IL-6. These results indicate a more selective inhibi- mutations surrounding the GC motif (Constructs C and
E) did not impact the response to apoptotic cells.tion of IL-12 p35 at the mRNA level.
IL-12 p35 Transcription Is Inhibited following A Nuclear Factor, GC-BP, Binds
to the IL-12 p35 PromoterPhagocytosis of Apoptotic Cells
The selective inhibition of IL-12 p35 mRNA expression By a combination of DNA affinity binding/purification
and mass spectrometry, we purified and identified aby apoptotic cells prompted us to focus on the transcrip-
tional mechanisms involved in the inhibition of the IL- novel, by virtue of its activity, zinc finger transcription
factor that specifically bound to the GCF element upon12 p35 gene expression. We used a well-established
transient transfection system in the mouse macrophage phagocytosis of apoptotic cells, but not necrotic cells,
or upon PS treatment of RAW264.7 macrophages (Fig-cell line RAW264.7 and a human IL-12 p35 promoter-
luciferase reporter (Grazia Cappiello et al., 2001). We ure 5A, pointed to by an arrow). Comparison of amino
acid sequences obtained with sequences in the data-found that phagocytosis of apoptotic cells, but not
necrotic cells, induced a profound inhibition of the full- base revealed that the protein was identical to the clone
of hypothetical protein FLJ13479. We named this factorlength (1082 to 61) IL-12 p35 promoter activity (Fig-
ure 4A, group #1). Deletion of a 65 bp region in the 3	 GC-BP for its ability to bind to the GC element, GCF.
The 619 amino acid sequence of GC-BP predictsend of the p35 promoter (group #2,1082/4) rendered
it totally resistant to the inhibitory effects of apoptotic strongly that it is a zinc finger-containing protein and
transcriptional repressor. PSORT II predicts with a verycells. However, two 5	 deletion constructs (groups #3
and #4) responded to apoptotic cells with the activity high probability and reliability (
95%) that it is a nuclear
protein with 16 putative C2H2-type zinc finger motifsof the full-length construct, thus suggesting that an apo-
ptotic cell response element is located downstream that could interact with DNA (Figure 5B). It has a calcu-
lated molecular weight of 68.3 kDa. The GC-BP geneof 4. To further elucidate the precise location of the
apoptotic cell response element, we investigated the appears to be unique in the mouse genome and is lo-
cated on chromosome 7. GC-BP, when expressed inregion between 4 and 61. By computer-assisted se-
quence analysis, three putative transcription factor recombinant form in a transcription/translation-coupled
reaction in rabbit reticulocyte lysates, specifically boundbinding sites were identified within this region of the IL-
12 p35 promoter: GCF (Kageyama and Pastan, 1989) to the IL-12 p35 promoter GCF site and forms three
complexes (marked as I, II, III in Figure 5C, lane 2). The(13 to 19), CTCF (Klenova et al., 1998) (4 to 8),
and ZEST (Park et al., 1998) (29 to 34). binding activities could be completely inhibited by an
excess of unlabeled wild-type GCF sequence (W, laneTo further delineate the precise response element,
mutagenesis by base substitutions was performed to 3), but far less efficiently by the mutant GCF sequence
(M, lane 4). The complexes, especially II and III, formeddisrupt these three sites. As shown in Figure 4B, muta-
tions of the entire 7 bp GCF site (Construct B), but not with GC-BP could be inhibited by the use of an anti-
GC-BP polyclonal Ab that we generated (see the Experi-the CTCF and ZEST mutants (data not shown), resulted
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Figure 4. Localization of the Apoptotic Cell
Response Element(s) in the IL-12 p35 Pro-
moter
The wild-type human IL-12 p35 promoter
(1082/61) or deletion/substitution mutant
constructs were linked to the firefly luciferase
reporter gene and transiently transfected into
RAW264.7 cells. Cells were treated with IFN-
together with an exposure to apoptotic Jurkat
cells for 16 hr, followed by stimulation of LPS
for 7 hr. Luciferase activities of all constructs
under all conditions were measured. Results
represent the mean  SD of three to four
individual experiments.
(A) Response of the IL-12 p35 deletion con-
structs.
(B) Response of the IL-12 p35 base substitu-
tion constructs. The nucleotides at13 to21
are depicted in the constructs. The underlined
crosses (X) indicate base substitutions by
transversion.
mental Procedures) (lane 6), but not by the control anti- derived macrophages (BMDMs) from mice and trans-
duced them with a retrovirus expressing the enhancedserum (lane 5). These data demonstrate the specificity
of the GC-BP/GCF interactions and confirm the ability green fluorescent protein (EGFP) or GC-BP plus EGFP
(bi-cistronic). The overall transduction efficiency wasof recombinant GC-BP, like its endogenous counterpart,
to interact with the same sequence element. 50% as judged by EGFP expression. GC-BP protein
overexpression in transduced cells was confirmed byTo determine if GC-BP could interact with the endoge-
nous, chromosomal IL-12 p35 gene, we performed chro- Western blot using the polyclonal GC-BP antibody (Fig-
ure 6D). The transduced cells were subjected to cellmatin immunoprecipitation (ChIP) assay in RAW264.7
cells by using the polyclonal anti-GC-BP antibody and sorting by FACS to select for EGFP positivity, which
yielded the EGFP high and low populations. Then, IL-a pair of PCR primers that directed the detection to
the region harboring the GCF. As shown in Figure 5D, 12 p40 and p70 production was measured by ELISA.
Due to the lack of an IL-12 p35-specific ELISA, andGC-BP-specific binding was strongly and specifically
detected in apoptotic cell-treated (lane 11), but not in the fact that IL-12 p70 is composed of p40 and p35
molecules in a 1:1 molar ratio, IL-12 p70 production wasuntreated (lanes 9 and 10) or necrotic cell-treated, mac-
rophages (lane 12), nor in control antibody-treated sam- used as an indirect indicator of IL-12 p35 synthesis.
There was an 65% inhibition of IL-12 p40 in GC-BP-ples (lanes 5–8). This result demonstrates unequivocally
that the native GC-BP could recognize its cognate bind- transduced BMDMs that were EGFP high and a slight
inhibition in the EGFP-low population (Figure 6E). GC-ing site on the IL-12 p35 gene promoter in response to
apoptotic cells. BP expression completely abrogated IL-12 p70 in the
EGFP-high macrophages, while it had little effect in EGF-
low cells (Figure 6F).Overexpression of GC-BP Results in Selective
Inhibition of IL-12 p35 Gene Expression
To determine if GC-BP could repress IL-12 p35 tran- Blocking GC-BP Expression by RNAi Results
in Restoration of IL-12 p35 Transcriptionscription, the IL-12 p35 promoter-reporter was cotrans-
fected into RAW264.7 cells with a GC-BP expression To further assess the role of the endogenous GC-BP in
IL-12 inhibition by phagocytosis of apoptotic cells, wevector. Expression of GC-BP dose dependently inhib-
ited IL-12 p35 transcription (Figure 6A), while the control applied the RNA interference (RNAi) technology to re-
duce endogenous GC-BP expression. We introduced avector PCR3.1 had little effect (Figure 6B). The inhibitory
effect by GC-BP, like that of apoptotic cells, was lost pool of three synthetic GC-BP-specific small interfer-
ence RNAs (siRNA) into IFN-/LPS-activated J774 cells,when the 1082/4 construct was used (Figure 6C),
indicating that GC-BP targets this region of the IL-12 and we showed that these siRNAs could efficiently and
specifically block the expression of GC-BP protein in ap35 promoter. Furthermore, GC-BP expression in J774
cells (mouse macrophage) resulted in a selective and dose-dependent manner; cyclin D1 expression, however,
was not affected under these conditions (Figure 6G).strong inhibition of IL-12 p35 mRNA induction by IFN-
and LPS, only marginal inhibition of the p40 mRNA, and Consistently, blocking GC-BP expression in J744 cells
by GC-BP-specific siRNAs resulted in a significant res-had no effect on IL-10 (data not shown).
To demonstrate the effect of GC-BP on IL-12 gene toration of IL-12 p35 mRNA expression inhibited by apo-
ptotic cells (compare column 9 to column 7, Figure 6H),expression in primary cells, we generated bone marrow-
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Figure 5. Identification of GC Binding Protein, GC-BP
(A) A DNA affinity binding assay was performed with GCF oligo as described in the Experimental Procedures. DNA bound proteins were eluted
and separated by SDS-PAGE gel. The fractionated proteins were visualized by Commassiee blue staining. A, apoptotic cells; N, necrotic cells;
P, PS; C, PC. The wild-type and mutant GCF sequences are displayed with the core sequence in bold and underlined.
(B) Conserved domains in GC-BP. The GC-BP sequence was subjected to a search through the NCBI Conserved Domain Database by using
RPS-Blast. Three types of conserved domains are identified: zinc finger (COG5048); HypF, hydrogenase maturation factor (posttranslational
modification, protein turnover, chaperones) (COG0068); SFP1, putative transcriptional repressor regulating G2/M transition (transcription/cell
division and chromosome partitioning) (COG5189).
(C) Recombinant GC-BP binding to the IL-12 p35 promoter. Recombinant GC-BP was synthesized in the transcription/translation (pTNT)-
coupled reaction in rabbit reticulocyte lysates and used in an EMSA with the GCF probe or the mutant GCF. The control was lysates derived
from the pTNT system expressing the firefly luciferase. In competition, 50 excesses (molar ratio) of unlabeled GCF oligo (W) or mutant GCF
(M) oligo were used. An anti-GC-BP polyclonal antiserum (G) and control antiserum (S) were used to demonstrate the specificity of the binding.
The same volume of lysates (2 l) was applied in all lanes.
(D) Chromatin immunoprecipitation (ChIP) assay. RAW264.7 cells were stimulated and fed with apoptotic cells or necrotic cells as described
in (A). ChIP analysis was performed with a polyclonal antiserum against murine GC-BP (lanes 9–12) or the control preimmunization bleed
(lanes 5–8). Input DNA (lanes 1–4) was isolated and analyzed the same way, with omission of the antibody treatment.
while the siRNAs had a slightly enhancing effect on basal Regulation of GC-BP Expression
and Tyrosine PhosphorylationmRNA expression (columns 2 and 3) and no effect on
IFN-/LPS-induced IL-12 p35 mRNA expression (col- To investigate the mode of activation of GC-BP in re-
sponse to apoptotic cells, we first examined its mRNAumn 6) in the absence of apoptotic cells.
The GC-BP-specific siRNAs caused a dramatic resto- expression, which was found to be constitutively pres-
ent in macrophage cells regardless of the activationration of IL-12 p70 production that was totally inhibited
following phagocytosis of apoptotic cells (compare col- state of the cell in the presence or absence of apoptotic
cells (data not shown). Western blot analysis of GC-BPumn 9 to column 7, Figure 6I) while having little effect
on the IL-12 p40 production (data not shown). Note that in RAW264.7 cells showed that there was no significant
difference in the level of GC-BP protein in resting versusIL-12 p70 is composed of p35 and p40 in a 1:1 molar
ratio. Although p40 production was not restored, the activated cells, in the nucleus versus the cytoplasm, or
in the absence or presence of apoptotic cells added atresidual amount of p40 was still considerably higher
than the amount of p70 produced. The use of siRNA in two different time points with respect to cell activation
by LPS (Figure 7A). These data indicate that GC-BPthe absence of apoptotic cells with or without LPS did
not have any specific impact on IL-12 p70 (columns 2 mRNA or protein expression as well as nuclear localiza-
tion are not regulated during phagocytosis of apoptoticand 3 and 5 and 6, Figures 6I).
These results confirm that apoptotic cell-induced GC- cells, and data suggest that its regulation may involve
posttranslational modifications of the protein.BP is a selective inhibitor of IL-12 p35 transcription.
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Figure 6. Effects of GC-BP on IL-12 p35 mRNA and Protein Expression
(A–C) Luciferase assay. The (A and B) full-length IL-12 p35 promoter-luciferase construct or the (C) 1082/4 deletion construct was
cotransfected with (A) expression vector GC-BP or the (B) control vector pCR3.1 into RAW264.7 cells by electroporation at molar ratios of
1:1 or 2:1 (effector:reporter). The next day, cells were stimulated by IFN- and LPS with (circle) or without (square) apoptotic cells. After 7 hr
of LPS stimulation, cells were lysed and luciferase activity was measured. Data represent the mean  SD of three independent experiments.
(D) GC-BP protein expression in transduced cells. Total cell lysates were isolated from retrovirally transduced macrophages and subjected
to Western blot analysis with the polyclonal anti-GC-BP antiserum. The membrane was subsequently stripped and reprobed with an anti-
cyclin D1 mAb (Santa Cruz) to confirm equal protein loading.
(E and F) EGFP- or GC-BP/EGFP-transduced macrophages were sorted based on the expression level of EGFP. A total of 1  106 cells of
GFP-BP or GC-BP/GFP high- and low-expressing macrophages were stimulated with IFN- and LPS as described above. (E) IL-12 p40 and
(F) IL-12 p70 were assayed from a cell-free culture supernatant by ELISA. The ELISA results are the meanSD from three individual experiments.
(G) A pool of three GC-BP-specific siRNAs or a control siRNA (luciferase) was introduced into J774 cells by Superfect reagent at several
concentrations as indicated following IFN- treatment, but 2 hr before LPS stimulation. Nuclear extracts from the transfected cells were
isolated 18 hr later, and 40 g each was subjected to Western blot analysis with the anti-GC-BP antibody. The blot was subsequently stripped
and reblotted with an anti-cyclin D1 antibody.
(H) IL-12 p35 mRNA expression in siRNA-transfected cells. J774 cells were sequentially stimulated with IFN- and LPS for 24 hr in the presence
or absence of apoptotic Jurkat cells. The GC-BP-specific siRNA pool or its control (luciferase) was transfected by Superfect reagent at the
concentration of 1 M 2 hr before the addition of LPS. Total RNA was isolated 4 hr after LPS stimulation and analyzed by real-time PCR for
mIL-12 p35 mRNA expression. For normalization, mRNA for GAPDH was analyzed. Data are expressed as relative expression to that of
unstimulated cells, set as 1.
(I) The production of IL-12 p70 was measured from supernatant of J774 cells following cellular stimulation and siRNA transfection as described
in (H). Supernatant was collected 24 hr following LPS stimulation. Results are the mean  SD of nine individual experiments.
As mentioned before, GC-BP has 16 putative zinc whereas a further deletion fragment down to the first
27 amino acids with only one phosphotyrosine motif stillfinger motifs throughout the protein and two phospho-
tyrosine motifs at amino acid 15 and 168, respectively. retained50% of the repressor activity of GC-BP (Figure
7B). This result prompted us to investigate the phosphor-To localize the responsible region for its IL-12 p35-inhib-
iting activity, we generated a series of C terminus trunca- ylation status of the endogenous GC-BP by coimmuno-
precipiation with phosphotyrosine-specific monoclonaltion constructs of GC-BP. Cotransfection of these trun-
cated GC-BP constructs with IL-12 p35 reporter showed antibodies. As shown in Figure 7C, GC-BP was constitu-
tively tyrosine phosphorylated (lane 1), and its level ofthat an N-terminal region (the first 198 amino acids)
containing the two putative phosphotyrosine motifs re- phosphorylation was enhanced in IFN-/LPS-stimulated
macrophages (lane 2). The increased phosphorylationtained the inhibitory effects of the full-length GC-BP,
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Figure 7. Protein Expression and Tyrosine Phosphorylation of GC-BP
(A) The RAW264.7 cell line was stimulated with IFN- and LPS alone or with apoptotic Jurkat cells that were added either 10 hr before (10 h)
or 4 hr after (4h) LPS stimulation. Nuclear and cytoplasmic proteins were prepared. A total of 20 g of proteins was analyzed on an 8%
SDS-PAGE gel and immuoblotted by a polyclonal rabbit antiserum specific for the N terminus of GC-BP. The question mark indicates a major
band of unknown nature. Neither of the two bands reacted with the control sera (prebleed) (not shown).
(B) Four C-terminal deletion constructs were generated by PCR from the full-length GC-BP construct (619 amino acids). Their lengths, in the
number of amino acids, as well as the number of remaining putative zinc finger (ZF) motifs are marked, as are the positions of the two
predicted phosphotyrosine sites at amino acids 15 and 168, respectively. Also indicated are their relative abilities to repress IL-12 p35 promoter
activity in transient cotransfections.
(C) Tyrosine phosphorylation of GC-BP in RAW264.7 cells. Nucelar extracts were prepared as described in (A) and were immunoprecipitated
with pY-99 AC for 4 hr at 4C. Then, the immunoprecipitated materials were analyzed by Western blot with the anti-GC-BP antibody. Total
GC-BP protein was measured as a control.
(D) The full-length IL-12 p35 promoter-luciferase reporter construct was cotransfected with GC-BP expression vector and its mutants Y15F
and Y168F, or with their control vector pCR3.1. Luciferase activity was measured, and the results represent the mean SD of three independent
experiments. Statistical analyses were done by Student’s t tests with the following: p** 0.0037, p*** 0.0086, and ns (not significant)  0.054.
was reduced by the addition of apoptotic cells (lane 3), by professional phagocytes is a critical mechanism in
generating a tolerant state to autoantigens in the im-but not by necrotic cells (lane 4), to macrophages. To
further determine the functional importance of the two mune system (Savill et al., 2002).
Here, we provide experimental evidence that signalsputative phosphorylation sites of GC-BP, we generated
two GC-BP mutants containing a tyrosine-to-phenylala- derived from apoptotic cells, probably through the inter-
action of the externalized PS with its receptors onnine conversion at amino acid residue 15 (Y15F) or 168
(Y168F) and tested their ability to repress IL-12 p35 phagocytes, induce the novel transcription factor GC-
BP that selectively represses IL-12 p35 transcription bypromoter activity (Figure 7D). Interestingly, the Y15F mu-
tant, but not the Y168F mutant, significantly abrogated binding to the GC dinucleotide at 17/18 of the p35
promoter. Apoptotic cells also potently inhibited IL-12the inhibitory effect of GC-BP on IL-12 p35 promoter
activity. This is consistent with the observation illus- p40 protein production. However, the IL-12 p40 mRNA
expression was only moderately inhibited by apoptotictrated in Figure 7B that deleting the region containing
Y168 made no functional difference compared to con- cells (Figure 3). Moreover, overexpression of GC-BP had
only a marginal inhibitory effect on IL-12 p40 mRNAstructs that retained only Y15. These data strongly sug-
gest that the activity of GC-BP may be regulated by expression, and blocking GC-BP by siRNA showed little
effect on IL-12 p40 protein synthesis. Although there ismodulation of tyrosine phosphorylation during phagocy-
tosis of apoptotic cells. a putative GC-BP binding site in the IL-12 p40 promoter
region (one nucleotide mismatched with the IL-12 p35
GCF site), overexpression of GC-BP only mildly re-Discussion
pressed IL-12 p40 transcription (data not shown). Taken
together, these data suggest that GC-BP is not a majorSuppression of the production of inflammatory cyto-
kines such as IL-12 during the clearance of dead cells transcriptional regulator of the IL-12 p40 gene in re-
Regulation of IL-12 Expression by Apoptotic Cells
651
sponse to apoptotic cells, which may inhibit IL-12 p40 regulated, with implications on the development and
expression principally by posttranscriptional mecha- pathogenesis of inflammatory and autoimmune dis-
nisms. The inhibition of IL-12 production is direct, rather eases.
than through autocrine production of TGF-1 or IL-10.
The mode of action of GC-BP is presently not under- Experimental Procedures
stood. It is conceivable that, based on the location of
Cells and Apoptosis Inductionthe GC-BP binding site immediately downstream of the
Human macrophages were isolated from peripheral blood mono-p35 transcription initiation site (TIS), it may act by imped-
cytes of normal donors and cultured with RPMI1640 supplementeding the progression or processivity of the RNA polymer-
with 10% heat-inactivated pooled human serum, L-glutamine, and
ase complex that traverses the IL-12 p35 gene during penicillin-streptomycin on 100 mm2 dishes for 5 days. On day 5,
transcription. In addition, the simultaneous loss of the macrophages were harvested by incubation with 5 mM EDTA in
apoptotic cell response and the elevated transcriptional PBS and plated in 24-well plates at 1  106 cell/well. Mouse mono-
cytic cell lines RAW264.7 and J774A.1 and human embryonic kidneyactivity following the mutation of the GC dinucleotide in
cell line HEK293 were obtained from ATCC.the IL-12 p35 promoter (Figure 4B) is interesting. It is
Peripheral blood-derived T cells from normal donors or Jurkatpossible that this element binds a protein that is a physi-
cells (human T cell line) were cultured in RPMI1640 supplementedologically relevant repressor of transcription in resting
with 10% FBS, L-glutamine, penicillin, and streptomycin. Normal
macrophages and in macrophages that are in contact T cells were activated by incubation with 2 g/ml PHA for 24 hr.
with apoptotic cells. However, it is equally likely that Nonadherent lymphocytes were collected and washed with medium
and then cultured at 106 cells/ml for 5 days in medium containingthese effects are unique to the transiently transfected
50 U/ml of recombinant human IL-2 (Chemicon International, Inc.).promoter-reporter plasmids and are not relevant to the
Apoptosis of Jurkat T cells or activated peripheral blood-derivedregulation of the endogenous gene. One way to prove
T cells was induced by incubation with 0.5 g/ml staurosporinethe in vivo significance/relevance of the GCF element
(Sigma-Aldrich) at 37C for 6–8 hr. The percentage of early- and
is to create a “knockout” cell in which this sequence late-apoptotic cells was quantified by flow cytometry analysis by
has been deleted from the endogenous chromosomal using Annexin V and propidium iodide (PI) staining according to the
IL-12 p35 gene. manufacturer’s instructions and was routinely 70%–80%. Distinc-
tion between apoptotic and necrotic cells was based on exclusionOur data indicate that both mRNA (not shown) and
of trypan blue as determined by light microscopy. Necrosis wasprotein expression of GC-BP are constitutive and not
induced by five cycles of freeze-thaw.regulated upon cell activation by LPS, by feeding with
apoptotic cells, or at the level of nuclear localization;
Generation of Bone Marrow Macrophagesyet, its DNA binding activity is enhanced by apoptotic
and Retrovirus Infectioncells and PS. These results suggest that GC-BP activity
Bone marrow-derived macrophage cultures were prepared as de-
is likely controlled by posttranslational modifications at scribed (Vollmar and Schulz, 1994). To deliver gene expression by
the protein level, or by its complexing with other proteins retrovirus, 30% of supernatant from the retrovirus-packaging cell
induced by apoptotic cells. Although GC-BP is predicted line gp2.293 infected with either the retroviral vector pMSCV.EGFP
alone or pMSCV.GC-BP/EGFP was added to macrophage cultureto contain 16 C2H2-type zinc finger domains, no more
plates on day 2 and day 4. The efficiency of gene transduction wasthan the first 5 of them within the N-terminal 198 amino
measured by GFP expression by FACS analysis.acids are critical for inhibitory activity on the IL-12 p35
transcription because deletion of the rest of the mole-
Antibodies and Reagentscule does not affect its ability to repress IL-12 p35 tran-
Anti-phosphotyrosine, pY99-AC, pY-102, and all other antibodiesscription (Figure 7B). Numerous potential phosphoryla-
used in the Western blots and supershift experiments were pur-tion sites are identified in the GC-BP protein sequence
chased from Santa Cruz Biotechnology. Anti-HA monoclonal anti-
by using the NetPhos 2.0 Prediction program: 28 serine body (mAb) was purchased from Covance. Recombinant human
(Ser), 9 threonine (Thr), and 2 tyrosine (Tyr) phosphoryla- and mouse IFN- was purchased from Genzyme. Cytochalasin D
tion sites. The two Tyr phosphorylation sites are particu- and LPS from Escherichia coli were purchased from Sigma. Syn-
thetic liposomes containing phosphatidylserine, phosphatidylcho-larly interesting because they are both located within
line, and phosphatidylethanolamine were purchased from Avanti.the “minimal” GC-BP functional protein (the N-terminal
The TNT Quick coupled Transcription/Translation System was pur-198 amino acids) at amino acid 15 and 168, respectively.
chased from Promega.We provided clear evidence that GC-BP is modulated
by tyrosine phosphorylation in the nucleus (Figure 7C).
Macrophage PhagocytosisFurthermore, mutation studies at the two putative tyro-
To quantify macrophage phagocytosis of apoptotic cells, a flowsine phosphorylation sites, Y15 and Y16,8 showed that
cytometric analysis modified from the method of (Mevorach et al.,
Y15 is functionally critical for the inhibitory activity of 1998) was used. In brief, peripheral blood-derived T cells or Jurkat
GC-BP (Figure 7D). T cells were labeled with the dye TAMRA (5-[and 6-]-carboxy tet-
The characteristics of GC-BP, such as its apparently ramethyl rhodamine succinimidyl ester, Molecular Probes) ac-
cording to the manufacture’s instructions. TAMRA-labeled cells“ubiquitous” expression (data not shown), suggest that
were then incubated with adherent macrophages for 1 hr at 37C.it may have broader activities than the transcriptional
After extensive washing, macrophages were released with trypsin-repression of IL-12 p35. It will be interesting to identify
EDTA, stained with FITC-anti-CD14 mAb, and analyzed by two-these additional activities of GC-BP. Discovery of the
color flow cytometry. Macrophages were gated by forward and side
potential target genes of GC-BP will provide a better scatter and CD14 positivity. Apoptotic cells that were not internal-
and more comprehensive understanding of the path- ized were excluded by this gating. The percentage of macrophages
ways and the framework in which GC-BP regulates the that ingested TAMRA-labeled target cells was calculated.
functions of various immune cell types.
In summary, the findings presented in this work signifi- Cytokine Determination
cantly enhance our understanding of an essential physi- IL-12 p40, p70, IL-10, and TGF- cytokine secretion was measured
by ELISA, according to protocols provided by BD-Pharmingen.ological process in which cytokine responses are tightly
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Plasmids TCGCTTTCATT and 3	 primer: ACTTTCCCGGGACTCTGGT) in a
buffer containing 2 mM MgCl2. The samples were amplified for 34A 1143 bp genomic fragment of the human IL-12 p35 promoter
derived from the clone AF050083 corresponding to nucleotide posi- cycles by PCR and were analyzed by electrophoresis on a 1.2%
agarose gel.tions 532–1675 was cloned into the pXP2 luciferase vector as a
BamHI-PstI fragment. The details are described in (Grazia Cappiello
et al., 2001). SiRNA
Chemically synthesized siRNA for GC-BP was designed by Design
Cloning of GC-BP Center (Dharmacon). The sequences are: GC-BP#1, 5	-GACAAGGU
Total RNA from the 4T1 mammary tumor cell line (Miller, 1983) was AUCAGCUUCAGdTdT-3	, GC-BP#2, 5	-GCAUUUGCUGAGCGAG
isolated and reverse transcribed, and GC-BP cDNA was amplified CUAdTdT-3	, and GC-BP#3, 5	-ACCUCUUGUGGCUUUGCUAd
by RT-PCR. The PCR primers used were: forward primer, 5	-TGGGG TdT-3	. A control siRNA for the luciferase gene was purchased from
AATGGAGTATTGGAA-3	, reverse primer, 5	CGTCAAGCTGACCCTT Dharmacon. RNA oligomers in water were annealed at a concentra-
CTTC-3	, based on the GenBank sequence BC030314. tion of 50 mM each with an initial hold at 90C for 1 min, followed
by a time-controlled cooling to room temperature. Transfection of
siRNAs for targeting endogenous genes was carried out by usingTransfections and Luciferase Assay
Superfect or Effectene (QIAGEN) and 1 M siRNA duplex per well.Transient transfection and luciferase assays were performed as pre-
HEK293 or RAW264.7 cell lines were transfected with siRNAs 1 hrviously described (Grazia Cappiello et al., 2001).
before apoptotic cell incubation. Transfection efficiency was deter-
mined by RT-PCR or Western blotting for the target gene.RNase Protection
RNase protection was performed by using the hCK-2 RiboQuant
Multiprobe Rnase Protection Assay system from BD-Pharmingen Generation of Polyclonal Anti-GC-BP Antibody
according to the manufacturer’s instruction. N-terminal GC-BP covering amino acids 1–231 was cloned into the
pRSET expression vector, which contains His tag at the C terminus
of GC-BP. Cloned GC-BP was transfected into the bacterial cellNuclear Extract Preparation
line, BL21(PE3)pLysS, and then treated with 1 mM IPTG for 4 hr toNuclear extracts for Western blotting and EMSA assays were pre-
induce GC-BP expression. The IPTG-treated bacteria was lysed inpared according to the method of Schreiber et al. (Schreiber et
Guanidinium Lysis buffer, and GC-BP was purified by using a Pro-al., 1989).
Bond Purification System (Invitrogen). Recombinant mouse GC-BP
was injected into rabbit. Following four injections (one primary plusDNA Affinity Binding Assay and Identification of GC-BP
three boosts), rabbit antiserum was obtained.The DNA affinity binding assay was performed essentially as we
described previously (Liu et al., 2003), by using 2 g biotinylated
DNA fragments encompassing the IL-12 p35 GCF element conju- Quantitative Real-Time PCR
gated to 100 l streptavidin bound magnetic beads (Dynabeads). To determine the level of IL-12 p35 mRNA by quantitative real-time
Bead-eluted proteins were separated by 10% SDS-PAGE gel and PCR, we used a modified protocol from (Rajeevan et al., 2001).
visualized by Coomassie blue or silver staining. For mass spectrom- Briefly, cDNA converted from 1g of total RNA was diluted to several
etry, an LCQ classic ion trap spectrometer with new objective emit- concentrations. Diluted cDNA was mixed with a pair of primers (10
ters of different sizes was used, and Sonar MS/MS software was M) derived from mouse IL-12 p35 or GAPDH cDNA sequences and
used for the protein identification from Rockefeller University core SYBR green PCR master mix (Applied Biosystem) in a 15 l volume.
facility. Protein analysis indicated that GC-BP was identical to the PCR cycling was as followed: 2 min at 50C, 10 min at 95C for 1
hypothetical protein FLJ13479 clone. (GenBank accession number cycle, followed by 40 cycles at 15 s at 95C and 1 min at 60C. The
BC030314; Protein ID: AAH30314). PCR primers used were: forward primer, 5	-AAATGAAGCTCTG
CATCCTGC-3	, reverse primer, 5	-TCACCCTGTTGATGGTCACG-3	
for mouse IL-12 p35; forward primer, 5	-AACT TTGGCATTGTGWestern Blotting and Immunoprecipitation
GAAGG-3	, reverse primer, 5	-ACACATTGGGGGTAGGAACA-3	 forSDS-PAGE was performed according to Laemmli (Laemmli, 1970)
mouse GAPCH.with 40 g nuclear extracts or total cell lysates depending on the
purpose of the experiments. Phospho-GC-BP was immmunopreci-
pitated from precleared extracts of an equivalent number of viable Acknowledgments
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